Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ANRO, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Bupropion | Major Depressive Disorder | Phase 4 · NCT04388189 | Withdrawn |
| ALTO-100 | Bipolar Disorder I or II With a Major Depressive Episode | Phase 2 · NCT06656416 | Recruiting |
| ALTO-100 PO Tablet | Major Depressive Disorder | Phase 2 · NCT05419869 | Completed |
| ALTO-101 | Schizophrenia | Phase 2 · NCT06502964 | Recruiting |
| ALTO-203 25 μg | Major Depressive Disorder | Phase 2 · NCT06391593 | Completed |
| ALTO-203 75 μg | Major Depressive Disorder | Phase 2 · NCT06391593 | Completed |
| ALTO-207 | Treatment-resistant Depression (TRD) | Phase 2 · NCT07553637 | Recruiting |
| ALTO-300 | Major Depressive Disorder | Phase 2 · NCT05922878 | Recruiting |
| ALTO-300 PO Tablet | Major Depressive Disorder | Phase 2 · NCT05157945 | Completed |
Also used in these trials (approved or third-party drugs, not ANRO's own candidates): Duloxetine, Escitalopram Oral, Sertraline.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ANRO holds $319.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $20.3M/quarter from operations, an estimated runway of 47.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 39 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ANRO files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Perceptive Advisors LLC | Institution (13G, 5%+) | 4,176,711 | 10.41% | 2026-06-30 |
| Alpha Wave Global, LP | Institution (13F) | 3,707,757 | 9.24% | 2026-09-30 |
| Commodore Capital LP | Institution (13G, 5%+) | 3,588,180 | 8.95% | 2026-03-31 |
| EcoR1 Capital, LLC | Institution (13G, 5%+) | 2,232,000 | 5.56% | 2026-07-13 |
| Sirenia Capital Management LP | Institution (13G, 5%+) | 2,219,568 | 5.53% | 2026-06-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 2,104,406 | 5.25% | 2026-06-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 1,970,108 | 4.91% | 2026-09-30 |
| Adage Capital Partners GP L.L.C. | Institution (13F) | 1,701,913 | 4.24% | 2026-09-30 |
| Spruce Street Capital LP | Institution (13F) | 1,676,558 | 4.18% | 2026-09-30 |
| Vivo Capital, LLC | Institution (13F) | 1,359,915 | 3.39% | 2026-09-30 |
| Price (T.Rowe) Associates Inc | Institution (13F) | 1,283,867 | 3.20% | 2026-09-30 |
| Franklin Resources, Inc. | Institution (13F) | 993,485 | 2.48% | 2026-09-30 |
Share count 40,110,620 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-10-02 filed 2026-10-05 |
Smith Nicholas Conrad |
Option exercise (M) | 55,000 | $2.32 | 79,060 |
| 2026-10-02 filed 2026-10-05 |
Smith Nicholas Conrad |
Option exercise (M) | 55,000 | – | – |
| 2026-09-30 filed 2026-10-01 |
Smith Nicholas Conrad |
Option exercise (M) | 24,056 | $2.35 | 48,116 |
| 2026-09-30 filed 2026-10-01 |
Smith Nicholas Conrad |
Sale (S) | 23,170 | $25.78 | 24,946 |
| 2026-09-30 filed 2026-10-01 |
Smith Nicholas Conrad |
Sale (S) | 886 | $26.87 | 24,060 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ANRO and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →